Interaction of spin-labeled HPMA-based nanoparticles with human blood plasma proteins - the introduction of protein-corona-free polymer nanomedicine
Language English Country England, Great Britain Media print
Document type Journal Article
PubMed
29560983
DOI
10.1039/c7nr09355a
Knihovny.cz E-resources
- MeSH
- Blood Proteins chemistry MeSH
- Humans MeSH
- Methacrylates chemistry MeSH
- Nanoparticles chemistry MeSH
- Nanomedicine MeSH
- Polyesters chemistry MeSH
- Polymers MeSH
- Protein Corona * MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- hydroxypropyl methacrylate MeSH Browser
- Blood Proteins MeSH
- Methacrylates MeSH
- polycaprolactone MeSH Browser
- Polyesters MeSH
- Polymers MeSH
- Protein Corona * MeSH
In this paper, we revised the current understanding of the protein corona that is created on the surface of nanoparticles in blood plasma after an intravenous injection. We have focused on nanoparticles that have a proven therapeutic outcome. These nanoparticles are based on two types of biocompatible amphiphilic copolymers based on N-(2-hydroxypropyl)methacrylamide (HPMA): a block copolymer, poly(ε-caprolactone) (PCL)-b-poly(HPMA), and a statistical HPMA copolymer bearing cholesterol moieties, which have been tested both in vitro and in vivo. We studied the interaction of nanoparticles with blood plasma and selected blood plasma proteins by electron paramagnetic resonance (EPR), isothermal titration calorimetry, dynamic light scattering, and cryo-transmission electron microscopy. The copolymers were labeled with TEMPO radicals at the end of hydrophobic PCL or along the hydrophilic HPMA chains to monitor changes in polymer chain dynamics caused by protein adsorption. By EPR and other methods, we were able to probe specific interactions between nanoparticles and blood proteins, specifically low- and high-density lipoproteins, immunoglobulin G, human serum albumin (HSA), and human plasma. It was found that individual proteins and plasma have very low binding affinity to nanoparticles. We observed no hard corona around HPMA-based nanoparticles; with the exception of HSA the proteins showed no detectable binding to the nanoparticles. Our study confirms that a classical "hard corona-soft corona" paradigm is not valid for all types of nanoparticles and each system has a unique protein corona that is determined by the nature of the NP material.
References provided by Crossref.org
HPMA Copolymer-Based Nanomedicines in Controlled Drug Delivery
Structure-to-Efficacy Relationship of HPMA-Based Nanomedicines: The Tumor Spheroid Penetration Study
Antibody-pHPMA functionalised fluorescent silica nanoparticles for colorectal carcinoma targeting